The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness: A Biomarker Study.
Phase of Trial: Phase II
Latest Information Update: 15 Jun 2016
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Biomarker; Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 03 Jun 2016 Planned End Date changed from 1 May 2016 to 1 Aug 2017.
- 03 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 Aug 2017.